|Over a week ago|
Valneva initiated with a Buy at Jefferies » 08:2306/0106/01/21
Jefferies analyst Maury…
Jefferies analyst Maury Raycroft initiated coverage of Valneva with a Buy rating and $36 price target. The company has three vaccine candidates in late-stage development along with a commercial base business, noted Raycroft, who thinks Valneva's history in the EU gives it "a low-profile perception" that creates an opportunity for U.S. investors. He calls out phase 3 data for chikungunya due in mid 2021 and results for the company's inactivated COVID-19 vaccine as upcoming catalysts with "upside potential."
Valneva initiated with a Buy at Goldman Sachs » 05:0106/0106/01/21
Goldman Sachs analyst…
Goldman Sachs analyst Graig Suvannavejh initiated coverage of Valneva with a Buy rating and $34 price target. Valneva is a French specialty vaccines company, with a portfolio that consists of two approved products, Dukoral for cholera and Ixiaro for Japanese encephalitis virus, as well as an emerging pipeline, Suvannavejh tells investors in a research note. The analyst views VLA15 as a "unique opportunity," given that there are no Lyme disease vaccines on the market.
Valneva initiated with a Buy at Guggenheim » 12:5805/3105/31/21
Guggenheim analyst Dana…
Guggenheim analyst Dana Flanders initiated coverage of Valneva with a Buy rating and $35 price target.
|Over a month ago|
Valneva opens at $30.47, IPO priced at $26.41 » 09:3705/0705/07/21
Valneva (VALN) priced…
Valneva (VALN) priced 3.5M shares at $26.41. Goldman Sachs acted as lead book running manager for the offering.
Valneva 3.5M share IPO priced at $26.41 » 06:3705/0605/06/21
Goldman Sachs acted as…
Goldman Sachs acted as lead book running manager for the offering.